Latest Study on Multiple Sclerosis Therapeutics to 2019

Albany, NY — (SBWIRE) — 09/16/2013 — GBI Research, the leading business intelligence provider, has released its latest research, “Multiple Sclerosis Therapeutics to 2019 Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth”. Currently there are a number of disease-modifying drugs in the Multiple Sclerosis (MS) market that are indicated for the treatment of relapsing forms of the disease, specifically reducing the frequency of disease relapses. The market is led by Copaxone, which achieved global sales of $4 billion in 2012.Complete Report @ http://www.researchmoz.us/multiple-sclerosis-therapeutics-to-2019-treatment-diversification-increasing-efficacy-and-pipeline-innovation-combine-to-drive-growth-report.htmlOver the forecast period 2012–2019, a variety of new drugs are due to enter the market that will offer a vast improvement in efficacy but also convenience, as many of these drugs are orally administered. Additionally, a high number of monoclonal Antibodies (mAbs) are due to enter the market and diversify it in terms of its portfolio for late stage or aggressive MS. All of these drugs have been shown to offer substantial improvements over current therapies. The price of these new therapies is expected to be high, particularly for the mAbs, but this is unlikely to hinder their uptake. As a result of this, as well as an overall increase in the treated population, read more